Breast cancer victims to be denied life-extending drug
Thursday 10 June 2010
Up to 2,000 women with advanced breast cancer will not be given access on the NHS to a drug that could extend their lives, it was announced yesterday.
GlaxoSmithKline (GSK), which makes Tyverb (lapatinib), said the medicine was an effective treatment for advanced breast cancer. But the National Institute for Health and Clinical Excellence (Nice) has rejected it for use on the NHS in England, citing high costs and the fact it only extends life by a few weeks.
Tyverb is a pill used in combination with the chemotherapy Xeloda (capecitabine) for women with hormone-sensitive advanced breast cancer. It is a last resort for those whose treatment with standard chemotherapies and Herceptin has failed.
According to GSK, Tyverb could increase survival by around three months compared with Xeloda alone. Tyverb is funded in 18 countries including the Czech Republic, Iceland, Slovakia and Slovenia.
However, in final draft guidance which is subject to appeal, Nice said the drug does "not represent good value for money when compared with the alternative... treatment". Sir Andrew Dillon, Nice's chief executive, said the watchdog had been looking at Tyverb for breast cancer since 2007.
"We are disappointed not to be able to recommend lapatinib but evidence suggests it only extends life by a small amount of time – around 10 weeks (2.4 months) – and costs thousands of pounds more than [a] more commonly used NHS treatment for this indication (Xeloda, capecitabine) on its own."
Maggie Alexander, director at Breakthrough Breast Cancer, said: "It is crucial to remember that this drug would not be suitable for all, and patients should speak to their doctor regarding appropriate treatments available to them."
elephant appealThe first 23 lots in our charity auction have now gone. But there are 22 more still up for grabs
Jennifer Lawrence attacks mass media again over body image
scienceScientists find the answer to a question that even puzzled Darwin
A very timely Great Train Robbery and a frantic 24 Hours in A&E among the highlights
scienceThe new development in bio-printing technology could be used in the future to restore lost vision - though years of research still await
Geoffrey Macnab: The Wolf of Wall Street's account of white-collar excess is A Rake’s Progress on steroids
arts + entsThe 'Friends' actor on his new role as campaigner on addiction issues
Life & Style blogs
The 10 Best Scotch Whiskies
Last orders looming for Trappist beers as Belgium's band of brotherly brewers dies off
Breakthrough in quantum computing smashes previous records
Facebook 'self-censorship': study records when you don't post to find more ways to share
Vitamin pills are a waste of money, offer no health benefits and could be harmful - study
- 1 Facebook 'self-censorship': study records when you don't post to find more ways to share
- 2 Sun will 'flip upside down' within weeks, says Nasa
- 3 ‘Why we don't have snow in Saudi Arabia’: Video captures winter fun as Middle East hit with rare blizzard
- 4 Vitamin pills are a waste of money, offer no health benefits and could be harmful - study
- 5 Children evacuated from swimming pool after prosthetic leg mistaken for paedophile
- < Previous
- Next >
£100 - £125 per day + Negotiable on role: Randstad Education London: Are you f...
£21000 - £30000 per annum: Randstad Education Leeds: A full time teacher job a...
£125 - £135 per day + Long Term Roles are negotiable: Randstad Education Londo...
£125 - £135 per day + negotiable for long term roles: Randstad Education Londo...